Cover Image
市場調查報告書

TCR&CAR改變T細胞及NK細胞療法 (2016年):各種技術的匯流造成的CD19 CART以外新的市場機會

TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of Technologies Opens Business Opportunities Beyond CD19 CARTs

出版商 La Merie Publishing 商品編碼 366651
出版日期 內容資訊 英文 388 Pages
訂單完成後即時交付
價格
Back to Top
TCR&CAR改變T細胞及NK細胞療法 (2016年):各種技術的匯流造成的CD19 CART以外新的市場機會 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of Technologies Opens Business Opportunities Beyond CD19 CARTs
出版日期: 2016年08月07日 內容資訊: 英文 388 Pages
簡介

本報告提供各種繼子細胞療法趨勢與企業的資金籌措方法調查,產業開發與授權趨勢,適合繼子細胞療法T細胞的製造趨勢,各種細胞療法的目前情形研究、開發趨勢,主要的成功因素和各種技術的匯流,主要經營者簡介,主要的細胞療法簡介等彙整資料。

第1章 摘要整理

第2章 簡介

第3章 企業的資金籌措

  • 股市
  • 聯盟契約
  • 初期階段的資金籌措 (VC、PE、其他)
  • 摘要 & 總論

第4章 產業開發 & 授權

  • 學術機構、產業間的官民聯盟
  • 企業聯盟 & 對外授權
  • 引入授權
  • 聯盟、合資企業
  • 企業及資產的收購

第5章 嵌合抗原受體 (CAR) T細胞療法的改良

  • 安全性的改善
  • 遺傳基因編輯
  • 有效性的改善
  • 通用CAR T細胞
  • 同類CAR T細胞

第6章 CAR T細胞的開發平台:競爭分析

  • CD19 CAR T細胞
  • CD19 CART的樞紐試驗
  • CD19 CART的中國企業的開發
  • 對骨髓惡性腫瘤的CAR T細胞
  • 對固態腫瘤的CAR T細胞
  • 中國的CAR T細胞的開發
  • 接取CAR的標的和CAR的標的發現

第7章 TCR改變T細胞

  • TCR T細胞的開發平台
  • TCR的標的發現

第8章 捐贈者淋巴球輸注 (DLI)

第9章 細胞傷害性T細胞 (CTL)

第10章 腫瘤浸潤性淋巴球 (TIL)

第11章 繼子細胞療法的T細胞的製造

  • 公司內部製造
  • 製造時間

第12章 自然殺手 (NK) 細胞

第13章 TCR & CAR T細胞療法的國際展望

第14章 主要成功因素、技術的匯流

第15章 企業簡介

  • 主要的醫藥品、生物科技企業
  • 美國、加拿大:技術&開發經營者
  • 歐洲:技術&開發經營者
  • 英國
  • 法國、比利時、義大利
  • 德國
  • 荷蘭、挪威、芬蘭
  • 亞洲
  • 日本、韓國
  • 中國

第16章 細胞療法簡介

  • CD19標的CAR T細胞療法
    • 4SCAR19
    • BPX-401
    • CBM-CD19.1
    • CD19 CAR T細胞 (第1代ZIOPHARM)
    • CD19 CAR T細胞 (第2代ZIOPHARM)
    • CTL019
    • CTL119
    • 完全人抗CD19 CAR T (NCI & Kite)
    • JCAR014
    • JCAR015
    • JCAR017
    • KTE-C19
    • UCART19
  • CD123標的CAR T細胞療法
    • CART123
    • MB-102
    • UCART123
  • BCMA標的CAR T細胞療法
    • bb2121
    • CART-BCMA
  • Fc標的CAR T細胞療法
    • ACTR087
    • ATTCK20
  • IL-13Rα2標的CAR T細胞療法
    • 抗IL-13Rα IgCD28TCR
    • MB-101
  • 其他固態腫瘤標的CAR T細胞療法
    • 抗CEA IgCD28TCR
    • 抗c-Kit IgCD28TCR
    • 抗GD3 IgCD28TCR
    • 抗PSMA IgCD28TCR
    • AU105
    • BPX-601
    • CART-EGFRVIII
    • CBM-EGFR.1
    • CSG-GPC3
    • JCAR020
    • JCAR023
    • JCAR024
    • OXB-302
  • 其他骨髓惡性腫瘤標的CAR T細胞療法
    • CAR-CD44v6
    • CBM-CD20.1
    • CBM-CD30.1
    • CD33 CAR
    • JCAR018
    • NKR-2
    • UCART38
    • UCARTCS1
  • MAGE (A3 / A4 / A10)標的TCR T細胞療法
    • MAGE A3 TCR (NCI & Kite)
    • MAGE A10c796 TCR
    • TB-1201
  • 胎兒球蛋白標的TCR & TCR先生T細胞療法
    • AFP-TCR
    • ET1402L1
  • NY-ESO-1標的TCR T細胞療法
    • NY-ESOc259; GSK9377794
    • TB-1301
  • WT1標的TCR T細胞療法
    • Autologous WT1 TCR
    • JTCR016
  • 其他標的TCR T細胞療法
    • BPX-701
    • TEG
  • 細胞傷害性淋巴球 (CTL) 療法
    • CMD-003; baltaleucel-T
    • CMV-CTL
    • Cytovir
    • EBV-CTL
    • WT1-CTL
  • 捐贈者淋巴球輸注 (DLI) 療法
    • BPX-501
    • Zalmoxis
  • 腫瘤浸潤性淋巴球 (TIL) 療法
    • LN-144
    • LN-145
  • 自然殺手 (NK) 細胞療法
    • aNK; Neukoplast; NK-92
    • haNK; CD16-Neukoplast
    • Her2.taNK
    • MG4101

第17章 參考文獻

圖表

目錄
Product Code: LMFR0020

The report “TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs” describes and analyzes the status of the adoptive cell therapy industry as of August 2016. The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. Cytotoxic lymphocytes (CTLs), donor lymphocyte infusions (TILs) and tumor infiltrating lymphocytes (TILs) complement the spectrum of the report.

The report highlights and discusses:

  • Company financing;
  • Business development & financing;
  • Improvements of CAR T-cell therapy incl. gene editing and universal CARTs;
  • Engineered TCR T-cells, including TCR target discovery;
  • The current status of DLIs, CTLs and TILs;
  • Manufacturing of T-cells for adoptive cell therapy;
  • NK cells and CAR engineered NK cells;
  • International perspective on TCR & CAR T-cell and NK cell therapy; and
  • Key success factors & convergence of technologies.

The early and impressive clinical results of anti-CD19 CAR T-cell therapy most probably will see confirmation in ongoing pivotal studies in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) leading to approval as early as 2017. Supported by Big Pharma money and billions of US$ by private financing rounds, public offerings and partnering money, Novartis, Juno Therapeutics and Kite Pharma are in a close race to be first on market with autologous CD19 CAR T-cell products. Cash-rich Juno and Kite went on a shopping and licensing tour to add numerous technologies like pearls on a string to be prepared for next generation development candidates.

However, clinical experience with CD19 CAR T-cells and other CAR T-cells for hematologic and solid tumors has revealed quite a number of hurdles. Part of them have to be addressed by protocol issues, such as the pre-conditioning chemotherapy problem, or clinical combination studies with checkpoint inhibitors to modulate the tumor micro-environment. But technological solutions are far more required to improve safety and efficacy as well as convenience and manufacturing of CAR T-cell therapies. Another big issue is the lack of strictly tumor-specific targets.

Among the key technologies are gene editing and TCR target discovery. Companies with such capabilities will have a strong position in financing, partnering and corporate development. This report describes the key players in the field and companies with complementary technologies ideal for joint ventures, or better, mergers.

The analytical evaluation in this report is based on retrieval of information about and detailed description of the profiles of 67 companies and 67 cell therapy product candidates. Information was obtained from 193 scientific references (abstracts, full papers, reviews), press releases, financial information, annual reports, presentations and webcasts. All information sources are fully referenced, either as scientific references or by hyperlinks embedded on the source description for online access to the source.

Who will benefit from this report?

  • Technology Officers
  • Corporate Development
  • Strategic Planning
  • Business Development & Licensing
  • Corporate Finance
  • Portfolio Management
  • Investors & Analysts
  • Clinical Development
  • Research & Development

Table of Contents

Abbreviations

1. Executive Summary

2. Introduction

3. Company Financing

  • 3.1. Stock Market
  • 3.2. Partnering Deals
  • 3.3. Early Stage Financing (VC, PE & Other Seed Money)
  • 3.4. Summary & Conclusions

4. Business Development & Licensing

  • 4.1. “Public-Private Partnerships” between Academia and Industry
  • 4.2. Corporate Alliances & Out-Licensing to Major Pharma & Biotech
  • 4.3. In-Licensing from Pharma & Biotech
  • 4.4. Collaborations & Joint Ventures
  • 4.5. Corporate & Asset Acquisitions

5. Improvement of Chimeric Antigen Receptor (CAR) T-Cell Therapy

  • 5.1. Improvement of Safety
    • 5.1.1. Role of pre-conditioning regimen
    • 5.1.2. Suicide genes as safety switch
    • 5.1.3. Elimination genes as safety switches
    • 5.1.4. Activation genes as safety switches
    • 5.1.5. Safety knock-out
    • 5.1.6. Tumor-specific activation
    • 5.1.7. Prodrug approach
    • 5.1.8. Safer T-cell signaling & activation
    • 5.1.9. Transient CAR expression
    • 5.1.10. Target selectivity & intratumoral delivery
  • 5.2. Gene Editing
  • 5.3. Improvement of Efficacy
    • 5.3.1. T-cell subsets
    • 5.3.2. Genetic modification of T-cells
    • 5.3.3. T-Cell activation & expansion
    • 5.3.4. CAR design: antigen-binding domain
    • 5.3.5. CAR design: linker/spacer and transmembrane domain
    • 5.3.6. CAR design: intracellular signaling domains
    • 5.3.7. CAR design: armored CARs against tumor microenvironment
    • 5.3.8. Immune checkpoint inhibition
    • 5.3.9. T-cell auto-antigen knock-out
    • 5.3.10. Target heterogeneity & target loss
  • 5.4. Universal CAR T-Cells
  • 5.5. Allogeneic CAR T-cells

6. Competitive CAR T-Cell Pipeline Analysis

  • 6.1. CD19 CAR T-Cells
  • 6.2. CD19 CART Pivotal Studies
  • 6.3. CD19 CART Developments by Chinese Companies
  • 6.4. Further CAR T-Cells against Hematologic Malignancies
  • 6.5. CAR T-Cells against Solid Tumors
  • 6.6. CAR T-Cell Developments in China
  • 6.7. Access to CAR Targets & CAR Target Discovery

7. Engineered TCR T-Cells

  • 7.1. TCR T-Cell Pipeline
  • 7.2. TCR Target Discovery
    • 7.2.1. SPEAR T-Cell Technology
    • 7.2.2. Naturally Selected TCRs (BioNTech)
    • 7.2.3. XPRESIDENT
    • 7.2.4. TCR-GENErator
    • 7.2.5. Single-Cell Sequencing (Juno)
    • 7.2.6. Natural, High Affinity TCRs (Bellicum)
    • 7.2.7. Sleeping Beauty Electroporation of TCRs
    • 7.2.8. Combinatorial T Cell Receptor Exchange (CTE)
    • 7.2.9. Tumor-Specific TCR Library (Medigene)
    • 7.2.10. Phagemers (Nextera)
    • 7.2.11. ALPHA Phage Display (Eureka)
    • 7.2.12. Epitarget (AIT)

8. Donor Lymphocyte Infusions (DLI)

9. Cytotoxic T-Lymphocytes (CTL)

10. Tumor Infiltrating Lymphocytes (TIL)

11. Manufacturing of T-Cells for Adoptive Cell Therapy

  • 11.1. In-House Manufacturing
  • 11.2. Manufacturing Time

12. Natural Killer (NK) Cells

13. International Perspective on TCR & CAR T-Cell Therapy

14. Key Success Factors & Convergence of Technologies

15. Company Profiles

  • 15.1. Major pharma & biotech companies
    • 15.1.1. Amgen
    • 15.1.2. Celgene
    • 15.1.3. Eli Lilly
    • 15.1.4. GlaxoSmithKline
    • 15.1.5. Janssen
    • 15.1.6. Merck KGaA
    • 15.1.6. Novartis
    • 15.1.7. ONO Pharmaceutical Co
    • 15.1.8. Pfizer
    • 15.1.9. Servier
    • 15.1.10. Shire (Baxalta)
  • 15.2. USA & Canada: technology and development companies
    • 15.2.1. Atara Biotherapeutics
    • 15.2.2. Aurora Biopharma
    • 15.2.3. Bellicum Pharmaceuticals
    • 15.2.4. Bluebird bio
    • 15.2.5. CytomX Therapeutics
    • 15.2.6. Eureka Therapeutics
    • 15.2.7. Formula Pharmaceuticals
    • 15.2.8. iCell Gene Therapeutics
    • 15.2.9. Intrexon
    • 15.2.10. Juno Therapeutics
    • 15.2.11. Kite Pharma
    • 15.2.12. Lion Biotechnologies
    • 15.2.13. MaxCyte
    • 15.2.14. Mustang Bio
    • 15.2.15. Nantkwest
    • 15.2.16. Poseida Therapeutics
    • 15.2.17. Precision BioSciences
    • 15.2.18. Sorrento Therapeutics
    • 15.2.19. TNK Therapeutics
    • 15.2.20. Triumvira Immunologics
    • 15.2.21. Unum Therapeutics
    • 15.2.22. Vor Biopharma
    • 15.2.23. ZIOPHARM Oncology
  • 15.3. Europe: technology & development companies
  • United Kingdom:
    • 15.3.1. Adaptimmune Therapeutics
    • 15.3.2. Autolus
    • 15.3.3. Catapult Therapy TCR
    • 15.3.4. Cell Medica
    • 15.3.5. Chimeric Therapeutics
    • 15.3.6. Leucid Bio
    • 15.3.7. Oxford BioMedica
    • 15.3.8. The Cell & Gene Therapy Catapult
  • France, Belgium & Italy
    • 15.3.9. Cellectis
    • 15.3.10. Celyad
    • 15.3.11. MolMed
    • 15.3.12. Theravectys
  • Germany
    • 15.3.13. BioNTech
    • 15.3.14. CPT - Cellex Patient Treatment & GEMoaB Monoclonals
    • 15.3.15. Immatics
    • 15.3.16. Medigene
    • 15.3.17. Miltenyi Biotec
  • The Netherlands, Norway & Finland
    • 15.3.18. Gadeta
    • 15.3.19. Nextera
    • 15.3.20. TILT Biotherapeutics
  • 15.4. Asia
  • Japan & Korea
    • 15.4.1. Green Cross Lab Cell
    • 15.4.2. Takara Bio
  • China
    • 15.4.3. American Yuva Biomed
    • 15.4.4. Beijing Doing Biomedical
    • 15.4.5. CARsgen Therapeutics
    • 15.4.6. Cellular Biomedicine Group
    • 15.4.7. Immune Therapeutics
    • 15.4.8. Innovative Cellular Therapeutics
    • 15.4.9. JW Biotechnology
    • 15.4.10. PersonGen BioTherapeutics
    • 15.4.11. Shanghai GeneChem
    • 15.4.12. Shenyang Sunshine Pharmaceutical
    • 15.4.13. Sinobioway Cell Therapy

16. Cell Therapy Profiles

  • 16.1. CD19-targeted CAR T-cell therapeutics:
    • 16.1.1. 4SCAR19
    • 16.1.2. BPX-401
    • 16.1.3. CBM-CD19.1
    • 16.1.4. CD19 CAR T-Cells (1st generation ZIOPHARM)
    • 16.1.5. CD19 CAR T-Cells (2nd generation ZIOPHARM)
    • 16.1.6. CTL019
    • 16.1.7. CTL119
    • 16.1.8. Fully human anti-CD19 CAR T (NCI & Kite)
    • 16.1.9. JCAR014
    • 16.1.10. JCAR015
    • 16.1.11. JCAR017
    • 16.1.12. KTE-C19
    • 16.1.13. UCART19
  • 16.2. CD123-targeted CAR T-cell therapeutics:
    • 16.2.1. CART123
    • 16.2.2. MB-102
    • 16.2.3. UCART123
  • 16.3. BCMA-targeted CAR T-cell therapeutics:
    • 16.3.1. bb2121
    • 16.3.2. CART-BCMA
  • 16.4. Fc-targeted CAR T-cell therapeutics:
    • 16.4.1. ACTR087
    • 16.4.2. ATTCK20
  • 16.5. IL-13Rα2-targeted CAR T-cell therapeutics:
    • 16.5.1. Anti-IL-13Rα IgCD28TCR
    • 16.5.2. MB-101
  • 16.6. Other solid tumor-targeted CAR T-cell therapeutics:
    • 16.6.1. Anti-CEA IgCD28TCR
    • 16.6.2. Anti-c-Kit IgCD28TCR
    • 16.6.3. Anti-GD3 IgCD28TCR
    • 16.6.4. Anti-PSMA IgCD28TCR
    • 16.6.5. AU105
    • 16.6.6. BPX-601
    • 16.6.7. CART-EGFRVIII
    • 16.6.8. CBM-EGFR.1
    • 16.6.9. CSG-GPC3
    • 16.6.10. JCAR020
    • 16.6.11. JCAR023
    • 16.6.12. JCAR024
    • 16.6.13. OXB-302
  • 16.7. Other hematologic malignancy-targeted CAR T-cell therapeutics:
    • 16.7.1. CAR-CD44v6
    • 16.7.2. CBM-CD20.1
    • 16.7.3. CBM-CD30.1
    • 16.7.4. CD33 CAR
    • 16.7.5. JCAR018
    • 16.7.6. NKR-2
    • 16.7.7. UCART38
    • 16.7.8. UCARTCS1
  • 16.8. MAGE (A3 / A4 / A10)-targeted TCR T-cell therapeutics:
    • 16.8.1. MAGE A3 TCR (NCI & Kite)
    • 16.8.2. MAGE A10c796 TCR
    • 16.8.3. TB-1201
  • 16.9. Alpha-Fetoprotein-targeted TCR & TCR-like T-cell therapeutics
    • 16.9.1. AFP-TCR
    • 16.9.2. ET1402L1
  • 16.10. NY-ESO-1-targeted TCR T-cell therapeutics
    • 16.10.1. NY-ESOc259; GSK9377794
    • 16.10.2. TB-1301
  • 16.11. WT1-targeted TCR T-cell therapeutics
    • 16.11.1. Autologous WT1 TCR
    • 16.11.2. JTCR016
  • 16.12. TCR T-cell therapeutics against other targets
    • 16.12.1. BPX-701
    • 16.12.2. TEG
  • 16.13. Cytotoxic T Lymphocyte (CTL) therapeutics
    • 16.16.1. CMD-003; baltaleucel-T
    • 16.13.2. CMV-CTL
    • 16.13.3. Cytovir
    • 16.13.4. EBV-CTL
    • 16.13.5. WT1-CTL
  • 16.14. Donor Lymphocyte Infusion (DLI) therapeutics
    • 16.14.1. BPX-501
    • 16.14.2. Zalmoxis
  • 16.15. Tumor Infiltrating Lymphocyte (TIL) therapeutics
    • 16.15.1. LN-144
    • 16.15.2. LN-145
  • 16.16. Natural Killer (NK) cell therapeutics
    • 16.16.1. aNK; Neukoplast; NK-92
    • 16.16.2. haNK; CD16-Neukoplast
    • 16.16.3. Her2.taNK
    • 16.16.4. MG4101

17. References. 360

Tables in the Text:

  • Table 1: Company Financing by Public Offerings
  • Table 2: Company Financing by Partnering Deals
  • Table 3: Company Financing by Venture Capital, Private Equity & Other Seed Money
  • Table 4: Investors in Early Stage T-Cell & NK Cell Technology Companies
  • Table 5: Total Amount of Money Globally Raised in 2015/16
  • Table 6: Total Amount of Money Raised in 2015/16 in Europe ONLY
  • Table 7: North America: Partnering with & In-Licensing from Academia
  • Table 8: Europe: Partnering with & In-Licensing from Academia
  • Table 9: Asia: Partnering with & In-Licensing from Academia
  • Table 10: Corporate Alliances & Out-Licensing to Major Pharma & Biotech
  • Table 11: In-Licensing from Pharma & Biotech
  • Table 12: Collaborations & Joint Ventures
  • Table 13: Corporate & Asset Acquisitions
  • Table 14: Gene Editing Technologies for Engineering of T-Cells
  • Table 15: Overview of Corporate Allogeneic CAR T-cell Developments
  • Table 16: Molecular & Cellular Characteristics of anti-CD19 CAR T-Cell Therapies under Corporate Development outside of China
  • Table 17: Competing anti-CD19 CARTs in Pivotal Studies
  • Table 18: Molecular & Cellular Characteristics of anti-CD19 CAR T-Cell Therapies under Corporate Development outside of China
  • Table 19: Molecular & Cellular Characteristics of Further CAR T-Cell Therapies against Hematologic Malignancies under Corporate Development outside of China
  • Table 20: Molecular & Cellular Characteristics of CAR T-Cell Therapies against Solid Tumors under Corporate Development outside of China
  • Table 21: Molecular & Cellular Characteristics of Further CAR T-Cell Therapies against Hematologic Malignancies under Corporate Development in China
  • Table 22: Molecular & Cellular Characteristics of CAR T-Cell Therapies against Solid Tumors under Corporate Development in China
  • Table 23: Pipeline of TCR T-Cell Therapy Candidates in Development with Company Participation
  • Table 24: Technologies for TCR Target Discovery and TCR T-Cell Generation
  • Table 25: Contract Manufacturing Organizations for T-cells
  • Table 26: Manufacturing Time of Selected TCR & CAR T-Cells and CTLs
  • Table 27: Bellicum's Switch and Costimulation Technologies
  • Table 28: Composition of Bellicum's T-Cell Product Candidates
  • Table 29: Bellicum's Pipeline of T-Cell Product Candidates
  • Table 30: Overview of Kite Pharma's Access to Technologies
  • Table 31: Overview of the Characteristics of Juno's CD19-Targeted CAR T-Cell Product Candidates
  • Table 32: Juno's Development Program of CD19 CAR-Ts
  • Table 33: Overview of the Characteristics of Juno's Further TCR & CAR T-Cell Product Candidates
  • Table 34: Juno's Clinical Development Program of Further TCR & CAR T-Cell Product Candidates
  • Table 35: Overview of Kite Pharma's Access to Technologies
  • Table 36: NCI-Initiated Clinical Studies of CAR & TCR T-Cell Product Candidates
  • Table 37: Overview of ZIOPHARM's R&D Pipeline
  • Table 38: Molecular & Cellular Characteristics of Cellectis' Allogeneic CAR T-Cells
  • Table 39: Early Clinical Trials with Autologous CAR T Cells from CBMG
  • Table 40: Early Clinical Trials of Sinobioway's CAR T-Cells
  • Table 41: Clinical Trials with CTL019
  • Table 42: Clinical Development Program of KTE-C19 CAR
  • Table 43: Early Clinical Trials with Adaptimmune's NY-ESOc259T
Back to Top